Weisberg, E., Liu, Q., Nelson, E., Kung, A. L., Christie, A. L., Bronson, R., . . . Gray, N. (2012). Using combination therapy to override stromal-mediated chemoresistance in mutant FLT3-positive AML: Synergism between FLT3 inhibitors, dasatinib/multi-targeted inhibitors, and JAK inhibitors: Novel combination therapy approaches to overriding stromal-mediated chemoresistance.

Weisberg, Ellen, et al. Using Combination Therapy to Override Stromal-mediated Chemoresistance in Mutant FLT3-positive AML: Synergism between FLT3 Inhibitors, Dasatinib/multi-targeted Inhibitors, and JAK Inhibitors: Novel Combination Therapy Approaches to Overriding Stromal-mediated Chemoresistance. 2012.

Weisberg, Ellen, et al. Using Combination Therapy to Override Stromal-mediated Chemoresistance in Mutant FLT3-positive AML: Synergism between FLT3 Inhibitors, Dasatinib/multi-targeted Inhibitors, and JAK Inhibitors: Novel Combination Therapy Approaches to Overriding Stromal-mediated Chemoresistance. 2012.